drugset / Trial / NCT05049863
Chemotherapy in Patients With Relapsed Small Cell Lung Cancer in Combination With Allopurinol and MycoPhenolate (CLAMP Trial)
Non-randomizedSequentialOpen-labelTreatment
Summary
The hypothesis is that the addition of mycophenolate mofetil (MMF) and allopurinol to chemotherapy in patients with relapsed small cell lung cancer (SCLC) will be safely tolerated and improve outcomes, as measured by response rate and progression-free survival in patients compared to other single agent chemotherapy drugs used in historical controls.
Timeline
- Start
- 2023-02-27
- Primary completion
- 2024-11-17
- Completion
- 2024-11-17
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Allopurinol | Small molecule | 300 mg | — |
| Subject | Irinotecan | Small molecule | 90 mg/m2 | — |
| Subject | Irinotecan | Small molecule | 100 mg/m2 | — |
| Subject | Mycophenolate Mofetil | Small molecule | 1 g | — |